About the Queensland Lung Transplant Service Research Centre
Lung Disease

About the Queensland Lung Transplant Service Research Centre

The Queensland Lung Transplant Service Research Centre is an internationally renowned research group that innovates to progress the current scientific understanding of the biology of lung diseases and conduct first-in-human trials to pioneer new therapies and bridge the ‘bench-to-bedside’ gap.

The group’s research to reduce the impact of post-lung transplant diseases and lung failure is critical. In 2022, there were more than 24 members of this research group conducting more than eight trials and studies.

Queensland Lung Transplant Service Research Centre’s Ground-breaking Research

The centre’s work advances the number of treatment options available for patients, increases the success of lung transplant procedures and ensures positive long-term outcomes for transplant recipients so they can maintain quality of life into the future.

Group members have been responsible for numerous world-first studies, along with research into post-lung transplant rejection.

Current projects include a focus on treatments and personalised medicine for lung disease. For example, ongoing research to develop new treatments for idiopathic pulmonary fibrosis (IPF) targets telomere maintenance and repair.

The centre also has active programs identifying biomarkers associated with transplant rejection and drug discovery looking at new treatments for pulmonary fibrosis.  Its lung fibrosis and lung transplantation clinical trial centre is one of the largest in the world.

A few Highlights for the Centre in 2022

In 2022, the centre had multiple clinical trials underway, including a multi-site trial to treat chronic lung allograft dysfunction (CLAD) with stem cells (ASSIST CLAD) – the world’s largest ever study of stem cell therapy for lung disease.

During the year, the centre’s multi-site trial to develop new treatments for patients with Silicosis (SHIELD), received widespread media attention. Supported by seed funding from the TPCH Foundation, it has conducted a world-first program of whole lung lavage for silicosis as part of this study.

New Collaborations for the Queensland Lung Transplant Service Research Centre

A new collaboration has been established with Pathology QLD to develop new treatments for antibody-mediated rejection.

Other new collaborations include The Centre of Research Excellence for Interstitial Lung Disease – towards Individualised Care; which has been funded by the NHMRC for five years from 2022.

Published: July 17, 2023

Related news & events

The journey from the Cycle of Giving to the Tour de Brisbane

The Common Good

The journey from the Cycle of Giving to the Tour de Brisbane

In 2006, Mary and Mal Long started an event called Cycle of Giving to show their gratitude to Mal’s donor family and medical team.

Find out more

Chain Reaction Challenge 2024: Helping Kids visiting The Prince Charles Hospital

The Common Good

Chain Reaction Challenge 2024: Helping Kids visiting The Prince Charles Hospital

In March, dozens of cyclists from Brisbane will take part in a 1000 km cycle in and around Adelaide for the Chain Reaction Challenge 2024.

Find out more

30-year-old heart transplant recipient’s journey to the 2024 Tour de Brisbane

Heart Disease

30-year-old heart transplant recipient’s journey to the 2024 Tour de Brisbane

A Perth father who received a heart transplant three years ago is preparing to take part in the 2024 Tour de Brisbane. Read more about his journey and support his ride here.

Find out more

International Day of Women and Girls in Science 2024

The Common Good

International Day of Women and Girls in Science 2024

This February, we acknowledge International Day of Women and Girls in Science 2024 and some of the remarkable women who are making a difference in STEM.

Find out more

Marfan and Aortopathy Conference Brisbane 2024

The Common Good

Marfan and Aortopathy Conference Brisbane 2024

The Marfan and Aortopathy Conference Brisbane 2024 is on Saturday, April 20, at The Prince Charles Hospital. Click here for more details.

Find out more

What is Marfan Syndrome?

The Common Good

What is Marfan Syndrome?

What is Marfan Syndrome? It affects about 1 in 5000 people across the globe, and for some, it can lead to serious or even life-threatening complications. Learn more here.

Find out more

The Café for The Common Good finds new home at Caboolture Hospital

Social Enterprise

The Café for The Common Good finds new home at Caboolture Hospital

Caboolture Hospital Café: In exciting news, our café has a new home in the hospital’s recently opened Clinical Services Building.

Find out more

Take a walk down Memory Lane at The Prince Charles Hospital

Ageing

Take a walk down Memory Lane at The Prince Charles Hospital

At The Prince Charles Hospital, patients and their families are encouraged to take a trip down the newly completed ‘Memory Lane’. Read about the impactful project here.

Find out more

2023 Year in Review

The Common Good

2023 Year in Review

The Common Good’s 2023 Year in Review: It’s been an impactful year thanks to our phenomenal supporters! Click here to read all about it.

Find out more